SL-28.
PreclinicalBiologic
SL-28. is one of 9 biologic programs targeting Head Neck Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Head Neck Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Vectibix
AmgenPhase 2
Beyfortus
BeiGenePhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 2
CD-001
CCD (Suzhou) Biopharma Co., Ltd.
Phase 1
SL-28.
SSecond Life Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SL-28.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- SSecond Life Therapeutics